Should You Buy Axsome Therapeutics Stock Before Feb. 23?

Core Insights - Axsome Therapeutics has experienced a significant stock increase of approximately 75% over the past 12 months, outperforming the S&P 500, which rose by 15% during the same period [1] - The company is set to report its quarterly results on February 23, 2026, which will include numbers for the last three months of 2025 and full-year results [2] Financial Performance - In its most recent earnings report for the period ending September 30, 2025, Axsome's revenue increased by 63% year-over-year, totaling $171 million, while the net loss decreased from $64.6 million to $47.2 million [5] - Despite the strong earnings, the stock price did not see a significant increase following the report, rising less than 2% a week later [6] Regulatory Developments - A major catalyst for the stock occurred on December 31, 2025, when regulators granted priority review for the company's Alzheimer's drug, AXS-05, with a target action date of April 30, 2026, leading to a 23% jump in shares on the announcement day [6] Market Valuation - Axsome's market capitalization has reached approximately $9.4 billion, but the company remains unprofitable and trades at a price-to-sales multiple of 16, indicating a potentially expensive investment [7] - The company's growth stage suggests that regulatory news may have a more significant impact on share price than earnings results, as evidenced by the stock's reaction to the AXS-05 news [8]